8 completed, 3 terminated, 2 not yet recruiting, 2 unknown. 16 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 8, Terminated 3, Not yet recruiting 2, Unknown 2, Active not recruiting 1 |
| Phase 2 | 7 | Completed 3, Not yet recruiting 2, Terminated 2 |
Follow Institut Paoli-Calmettes: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers M1774, Fulvestrant injection - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 57 | 2024-05-01 | 2024-03-29 |
| A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr Niraparib Oral Product - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 72 | 2023-03-01 | 2022-08-29 |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB - Metastatic Cancer, Metastatic Breast Cancer | Phase 1 | Active not recruiting | Institut Paoli-Calmettes | 27 | 2022-01-21 | 2026-06-22 |
| Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes Fludarabine-Cladribine-Busulfan conditioning regimen - Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute | Phase 1 | Unknown | Institut Paoli-Calmettes | 29 | 2018-04-28 | 2018-06-28 |
| HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies HLA-mismatched microtransplantation - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Institut Paoli-Calmettes | 25 | 2018-03-09 | 2026-10-14 |
| A Study to Assess the Efficacy and Safety of ABTL0812 ABTL0812 in combination with paclitaxel and carboplatin - Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Ability Pharmaceuticals SL | 103 | 2016-12-01 | 2023-02-22 |
| Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation Monalizumab - Hematologic Malignancies | Phase 1 | Unknown | Institut Paoli-Calmettes | 18 | 2016-11-28 | 2018-09-19 |
| Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide - Non Castrate Metastatic Prostate Cancer | Phase 1 | Terminated | Institut Paoli-Calmettes | 6 | 2014-10-01 | 2017-11-17 |
| Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer Nab-paclitaxel + Gemcitabine - Pancreatic Adenocarcinoma | Phase 1 | Completed | Institut Paoli-Calmettes | 19 | 2014-09-01 | 2017-03-28 |
| Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer LY2780301 + paclitaxel - Breast Cancer | Phase 1 / Phase 2 | Terminated | Institut Paoli-Calmettes | 68 | 2014-01-01 | 2026-04-21 |
| Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation NK Cell infusion - Hematological Malignancy | Phase 1 | Completed | Institut Paoli-Calmettes | 17 | 2013-04-01 | 2026-04-21 |
| Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy recwt1-A10+AS01B - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Institut Paoli-Calmettes | 2 | 2013-03-01 | 2015-03-20 |
| Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer BKM120 + lapatinib - Breast Cancer | Phase 1 / Phase 2 | Terminated | Institut Paoli-Calmettes | 24 | 2011-12-01 | 2026-04-21 |
| Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia amsacrine, busulfan, cytarabine - Leukemia | Phase 1 / Phase 2 | Completed | Institut Paoli-Calmettes | 135 | 2009-01-01 | 2011-05-13 |
| Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission therapeutic autologous dendritic cells - Leukemia | Phase 1 | Completed | Institut Paoli-Calmettes | 10 | 2008-06-01 | 2011-05-13 |
| Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm Vinorelbine, Cyclophosphamide and Interferon alpha 2b - Advanced Neoplasm | Phase 1 | Completed | Institut Paoli-Calmettes | 30 | 2006-05-01 | 2012-01-30 |
Breast Neoplasms (5) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Congenital Abnormalities (2) · Endometrial Neoplasms (2) · Hematologic Neoplasms (2) · Leukemia (2) · Esophageal Neoplasms (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Acute (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
NVP-BKM120 (2) · Paclitaxel (2) · 130-nm albumin-bound paclitaxel (1) · ABTL0812 (1) · Amsacrine (1) · Buserelin (1) · Busulfan (1) · Carboplatin (1) · Cyclophosphamide (1) · Cytarabine (1) · Daunorubicin (1) · Drug Therapy (1) · Fulvestrant (1) · Gemcitabine (1) · Immunotherapy, Active (1)
France (14) · Spain (1)
Ana Oaknin (1) · Christian Chabannon, MD, PhD (1) · Norbert Vey, MD (1) · Raynier Devillier, MD,PhD (1)
PMID 28950146, PMID 32718876, PMID 34071607, PMID 34781168, PMID 35122700, PMID 35293148, PMID 39039449
2016 (1)